文献速递产科母胎医学

子宫托与阴道黄体酮预防宫颈长度小于38毫米双胎妊娠早产比较:一项随机对照试验

Pessary Compared With Vaginal Progesterone for the Prevention of Preterm Birth in Women With Twin Pregnancies and Cervical Length Less Than 38 mm: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2019-01-01

在越南美德医院开展的随机对照试验纳入300例无症状双胎妊娠且宫颈长度小于38毫米孕妇,比较阿拉伯子宫托与阴道黄体酮400毫克每日一次。子宫托组与黄体酮组34周前早产率无显著差异,但子宫托显著降低不良围产结局复合指标;宫颈长度≤28毫米亚组中子宫托显著降低34周前早产率。

要点

  • 子宫托组与黄体酮组34周前早产率无显著差异(16% vs 22%,RR 0.73,95%CI 0.46-1.18)。
  • 子宫托显著降低不良围产结局复合指标(19% vs 27%,RR 0.70,95%CI 0.43-0.93)。
  • 宫颈长度≤28毫米者子宫托显著降低34周前早产率(21% vs 46%,RR 0.47,95%CI 0.24-0.90)。

核心结论

  • 在双胎妊娠且宫颈长度小于38毫米的无症状孕妇中,子宫托与400毫克阴道黄体酮的34周前早产率相似。

研究设计与样本

  • 在越南美德医院开展的随机对照试验,纳入300例无症状双胎妊娠且宫颈长度小于38毫米孕妇,每组150例,按意向治疗分析。
  • 样本量估算基于黄体酮组主要结局发生率28.4%,需290例以检测14%绝对风险差异(把握度80%,α误差5%,失访10%)。

主要发现

  • 34周前早产发生于子宫托组24例(16%)与黄体酮组33例(22%)(RR 0.73,95%CI 0.46-1.18)。
  • 子宫托显著降低不良围产结局复合指标(子宫托组19% vs 黄体酮组27%;RR 0.70,95%CI 0.43-0.93)。
  • 宫颈长度≤28毫米(第25百分位)者中,子宫托显著降低34周前早产率(子宫托组21%(10/47) vs 黄体酮组46%(16/35);RR 0.47,95%CI 0.24-0.90),并显著改善不良围产结局复合指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effectiveness of cervical pessary to vaginal progesterone for the prevention of preterm birth in women with twin pregnancies and short cervix. METHODS: This randomized controlled trial was conducted at My Duc Hospital, Vietnam. Asymptomatic women with twin pregnancies and cervical length less than 38 mm were randomized to Arabin pessary or vaginal progesterone (400 mg once a day) group. The primary outcome was preterm birth at less than 34 weeks of gestation. Secondary outcomes were adverse maternal and perinatal complications. We planned a subgroup analysis according to quartile of cervical length. Analysis was conducted on an intention-to-treat basis. We estimated that the primary outcome would occur in 28.4% of women treated with progesterone. Thus a total sample size of 290 women divided equally into two groups was required to detect a 14% absolute risk difference in the primary outcome between the two groups (power 80%, alpha-error 5%, 10% loss to follow-up). RESULTS: Between March 2016 and June 2017, we randomized 300 women, 150 women in each group. Preterm birth at less than 34 weeks of gestation occurred in 24 (16%) women in the pessary group and 33 (22%) women in the progesterone group (relative risk [RR] 0.73, 95% CI 0.46-1.18). The use of pessary significantly reduced the composite of poor perinatal outcomes (19% vs 27%; RR 0.70, 95% CI 0.43-0.93). In women with cervical length of 28 mm or less (25th percentile), pessary significantly reduced the preterm birth rate at less than 34 weeks of gestation from 46% (16/35) to 21% (10/47) (RR 0.47, 95% CI 0.24-0.90) and significantly improved the composite of poor perinatal outcomes. CONCLUSION: Cervical pessary and 400 mg vaginal progesterone resulted in similar rates of preterm birth at less than 34 weeks of gestation in women with twin pregnancies and cervical length less than 38 mm. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02623881.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dang VQ, Nguyen LK, Pham TD, et al. Pessary Compared With Vaginal Progesterone for the Prevention of Preterm Birth in Women With Twin Pregnancies and Cervical Length Less Than 38 mm: A Randomized Controlled Trial. Obstet Gynecol. 2019. PMID: 30741812. doi:10.1097/AOG.0000000000003136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。